Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).
An international consensus on pancreatic cancer testing standardizes which genetic mutations to hunt and how to match patients with precision therapies.
A Chinese multidisciplinary expert consensus published in British Journal of Cancer standardizes precision molecular testing for pancreatic cancer, including NGS panel selection, actionable mutation identification (KRAS, BRCA1/2, NTRK, MSI-H), liquid biopsy recommendations, and molecular therapy matching guidelines. The international venue publication suggests the consensus is positioned as a global resource for one of oncology's most lethal and diagnostically challenging malignancies.
What the study was
- Study design
- Expert consensus/clinical guideline (multidisciplinary Chinese panel, published in high-impact journal)
- Population
- Patients with pancreatic cancer or high-risk individuals requiring precision molecular testing
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- British journal of cancer
Why it surfaced
Expert consensus on precision molecular diagnosis of pancreatic cancer published in British Journal of Cancer. Pancreatic cancer has catastrophic prognosis; standardized precision testing consensus is directly actionable for clinical laboratories and oncologists. International publication signals global relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.